Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05157191 · ClinicalTrials.gov registry record

Safety of Pediatric COVID-19 Vaccination

A clinical trial of Pain and Adverse Drug Event, sponsored by Duke University.

Completed
Registry status
299
Enrollment target
5
Study locations

NCT05157191: Completed study of Pain and Adverse Drug Event, sponsored by Duke University.

NCT05157191 is a study of Pain and Adverse Drug Event that has completed, run by Duke University. The registered enrollment target is 299 participants, roughly in line with the 303-participant average among 374 other Pain trials with a reported enrollment target. The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05157191, a study of Pain and Adverse Drug Event, has completed, sponsored by Duke University.

COMPLETED
Registry status
299 participants
Enrollment target
5
Study locations

Study Summary

This is a prospective, observational study. During the study, children and adolescents (ages ≥ 5 to \< 16) will be followed post administration of mRNA COVID-19 vaccines. Injection site (local), systemic reaction, and unsolicited adverse event data will be assessed on vaccination day and during the 7 days following each vaccination using either identical web-based or paper diaries, depending on study participant preference. At Duke University, Cincinnati's Children Hospital, and Kaiser Permanente Northern California, serum samples will be collected for optional assessment of antibody titers to COVID-19. Each participant who opts in will have baseline (within 3 days of vaccination) serologies obtained and immunogenicity assessment at 28 (+7) days after each dose. All participants will be followed for 180 days after dose 2 for serious adverse events and adverse events of special interest.

Primary Outcome

Tables summarizing each solicited local and systemic reactogenicity event by maximum classification (none, mild, moderate, and severe), as well as by moderate or severe

Interventions

  • OTHER Observational

Study Locations (5)

California

  • Kaiser Permanente Northern California - Oakland

Georgia

  • Centers for Disease Control and Prevention - Atlanta

New York

  • Columbia University - New York

North Carolina

  • Duke University - Durham

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati

Trial Details

FieldValue
Enrollment Target 299 participants
Start Date 2022-04-06
Est. Completion 2023-10-27
Duke University

1,725 total trials

What the finished NCT05157191 record still lists

NCT05157191 is an observational study that tracks outcomes without assigning an intervention. The registered 299 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 303-participant average among 374 other Pain trials with a reported enrollment target.

The record links to 3 conditions, with Pain appearing as the primary indexed condition, and to 1 intervention - of which Observational is the first listed.

NCT05157191 lists 5 locations in 5 states (California, Georgia, New York).

Frequently Asked Questions

What is clinical trial NCT05157191 about?

NCT05157191 is a clinical study titled "Safety of Pediatric COVID-19 Vaccination". This is a prospective, observational study. During the study, children and adolescents (ages ≥ 5 to \< 16) will be followed post administration of mRNA COVID-19 vaccines. Injection site (local), systemic reaction, and unsolicited adverse event data will be assessed on vaccination day and during the...

What is the current status of trial NCT05157191?

This trial is currently completed. The enrollment target is 299 participants. The study started on 2022-04-06. Estimated completion is 2023-10-27.

What conditions does trial NCT05157191 study?

This clinical trial studies the following conditions: Pain, Adverse Drug Event, Injection Site Reaction.

What interventions are being tested in trial NCT05157191?

The interventions under investigation include: Observational (OTHER).

Who is sponsoring clinical trial NCT05157191?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05157191 being conducted?

This trial has 5 study locations across California, Georgia, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05157191's enrollment target sits among peer trials

299 61st of 374 higher than 312 of 374 other Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05157191, the US trial registry maintained by the National Library of Medicine. NCT05157191 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.